Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 1;15:1417851. doi: 10.3389/fphar.2024.1417851

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Scuteri, Pagliaro, Mantia, Contrada, Pignolo, Tonin, Nicotera, Bagetta, Corasaniti and the Pilot BRAINAID Trial investigators.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Efficacy of NanoBEO on disruptiveness of agitation based on the CMAI-D scores during treatment and follow-up (A) and as individual data at baseline and after 2 weeks of treatment (B); data are expressed as the median + IQR. Patients allocated to the NanoBEO group experienced a reduction in CMAI-D scores than did patients allocated to the placebo group. (C) Statistically significant differences regarding NanoBEO efficacy were observed for all time points versus baseline (data are expressed as the mean ± SEM; time factor ****p < 0.0001; participant matching ****p < 0.0001; NanoBEO: 2 weeks **p < 0.01; 4, 6 and 8 weeks ***p < 0.001). *p values <0.05 indicate statistical significance. n: NanoBEO = 14, placebo = 16.